Overview Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C Status: Recruiting Trial end date: 2026-06-01 Target enrollment: Participant gender: Summary This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients. Phase: Phase 2 Details Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris